Combined role of PEAR1 and GP genes in the mechanism of aspirin resistance and its clinical significance

  • Yu Ning Beihua University Affiliated Hospital, Jilin 132001, China
  • Yan Gao Beihua University Affiliated Hospital, Jilin 132001, China
  • Wei Gao Jilin City People’s Hospital, Jilin 132001, China
DOI: https://doi.org/10.62617/mcb1091
Keywords: PEAR1 gene; GP gene; aspirin; resistance mechanism; binary logic analysis
Article ID: 1091

Abstract

Exploring the mechanism of aspirin resistance helps to improve the prevention and treatment of ischemic stroke diseases and reduce the interference of resistance mechanism on the therapeutic effect of aspirin. In this paper, the Affiliated Hospital of Beihua university, together with two other hospitals, was chosen as the research unit, from which 260 AIS patients were selected for aspirin resistance study. The joint role of PEAR1 gene and GP gene in the mechanism of aspirin resistance was discussed by genotyping, TEG assay, univariate analysis, and binary logistic analysis methods. Among the GP1BA genes in AIS patients, the frequency of CC-type genes was as high as 92.03%, and the risk of aspirin resistance was significantly increased in CC-type relative to TT-type. The incidence of rs5924 allele T was significantly higher in the AR group than in the AS group (OR = 1.632, p = 0.006), and there was a significant effect of diabetic conditions on aspirin resistance at the 1% level. Diabetes significantly inhibits plasma proteins in AIS patients and makes aspirin less inhibitory to platelets. Therefore, clarifying the influence of PEAR1 and GP genes in the mechanism of aspirin resistance can be used to obtain the precise loci from the gene therapy point of view to enhance the disease treatment effect of aspirin.

References

1. Powers, W. J. (2020). Acute ischemic stroke. New England Journal of Medicine, 383(3), 252-260.

2. Walter, K. (2022). What is acute ischemic stroke?. Jama, 327(9), 885-885.

3. Sommer, C. J. (2017). Ischemic stroke: experimental models and reality. Acta neuropathologica, 133(2), 245-261.

4. Khoshnam, S. E., Winlow, W., Farzaneh, M., Farbood, Y., & Moghaddam, H. F. (2017). Pathogenic mechanisms following ischemic stroke. Neurological Sciences, 38, 1167-1186.

5. Mendelson, S. J., & Prabhakaran, S. (2021). Diagnosis and management of transient ischemic attack and acute ischemic stroke: a review. Jama, 325(11), 1088-1098.

6. Catanese, L., Tarsia, J., & Fisher, M. (2017). Acute ischemic stroke therapy overview. Circulation research, 120(3), 541-558.

7. Barthels, D., & Das, H. (2020). Current advances in ischemic stroke research and therapies. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1866(4), 165260.

8. Hermann, D. M., & Kleinschnitz, C. (2019). Modeling vascular risk factors for the development of ischemic stroke therapies. Stroke, 50(5), 1310-1317.

9. Heo, J., Youk, T. M., & Seo, K. D. (2021). Anemia is a risk factor for the development of ischemic stroke and post-stroke mortality. Journal of Clinical Medicine, 10(12), 2556.

10. Vasudeva, K., & Munshi, A. (2019). Genetics of platelet traits in ischaemic stroke: focus on mean platelet volume and platelet count. International Journal of Neuroscience, 129(5), 511-522.

11. Yi, X., Lin, J., Luo, H., Wang, C., & Liu, Y. (2017). Genetic variants of PTGS2, TXA2R and TXAS1 are associated with carotid plaque vulnerability, platelet activation and TXA2 levels in ischemic stroke patients. PLoS One, 12(7), e0180704.

12. Alqahtani, Z., & Jamali, F. (2018). Clinical outcomes of aspirin interaction with other non-steroidal anti-inflammatory drugs: a systematic review. Journal of Pharmacy & Pharmaceutical Sciences, 21(1s), 48s-73s.

13. Xu, X. R., Yousef, G. M., & Ni, H. (2018). Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood, The Journal of the American Society of Hematology, 131(16), 1777-1789.

14. Hannachi, N., Baudoin, J. P., Prasanth, A., Habib, G., & Camoin-Jau, L. (2020). The distinct effects of aspirin on platelet aggregation induced by infectious bacteria. Platelets, 31(8), 1028-1038.

15. Wu, Q. L., Dong, J., Zeng, H. W., Lv, C., Liu, A. J., & Zhang, W. D. (2020). Monitoring antiplatelet aggregation in vivo and in vitro by microtiter plate method. Journal of cardiovascular pharmacology, 75(4), 314-320.

16. Alyavi, A. L., Khodjanova, S. I., Uzokov, J. K., & Kadirova, S. (2021). Aspirin resistance in patients with chronic coronary syndrome. Indian Journal of Forensic Medicine & Toxicology, 15(3), 1843-1846.

17. Zimmermann, P., & Curtis, N. (2018). The effect of aspirin on antibiotic susceptibility. Expert Opinion on Therapeutic Targets, 22(11), 967-972.

18. Christiansen, M., Grove, E. L., & Hvas, A. M. (2021, October). Contemporary clinical use of aspirin: mechanisms of action, current concepts, unresolved questions, and future perspectives. In Seminars in Thrombosis and Hemostasis (Vol. 47, No. 07, pp. 800-814). Thieme Medical Publishers, Inc..

19. Baturina, O., Andreev, D., Fedina, L., Mirzaev, K., Ivashchenko, D., Ryzhikova, K., ... & Sychev, D. (2022). Influence of clinically significant genes on antiplatelet effect of clopidogrel and clinical outcomes in patients with acute coronary syndrome and atrial fibrillation. Pharmacology, 107(3-4), 216-226.

20. O’connor, C. T., Kiernan, T. J., & Yan, B. P. (2017). The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Expert opinion on drug metabolism & toxicology, 13(7), 725-739.

21. Wen Zhou,Bin Zhang,Keyu Fan,Xiaojian Yin,Jinfeng Liu & Shaohua Gou. (2021). An Original Aspirin-Containing Carbonic Anhydrase 9 Inhibitor Overcomes Hypoxia-Induced Drug Resistance to Enhance the Efficacy of Myocardial Protection. Cardiovascular Drugs and Therapy(4),1-14.

22. Ma Ji,Fan Zhenhai,Tang Qiulin,Xia Hongwei,Zhang Tao & Bi Feng. (2020). Aspirin attenuates YAP and β-catenin expression by promoting β-TrCP to overcome docetaxel and vinorelbine resistance in triple-negative breast cancer. Cell death & disease(7),530.

23. Yi Xingyang,Wang Chun,Zhou Qiang & Lin Jing. (2017). Interaction among COX-2, P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients. BMC neurology(1),4.

24. Lucas Sobral de Rossi,Raquel Pires Nakama,Lucas Felipe Dos Santos,Leonardo Berto Pereira,Aparecida Donizette Malvezi,Maria Isabel Lovo Martins... & Phileno Pinge Filho. (2024). Metabolic syndrome promotes resistance to aspirin in mitigating bone loss in murine periodontal disease. Life Sciences123224-123224.

25. Jun Liu,Linkun Pan,Sheng Wang,Yueran Li,Yilai Wu,Jiajie Luan & Kui Yang. (2024). Predicting laboratory aspirin resistance in Chinese stroke patients using machine learning models by GP1BA polymorphism. Pharmacogenomics11-12.

26. Parsa kondelaji Mohammad & Mansouritorghabeh Hassan. (2023). Aspirin and clopidogrel resistance; a neglected gap in stroke and cardiovascular practice in Iran: a systematic review and meta-analysis. Thrombosis Journal(1),79-79.

Published
2024-12-27
How to Cite
Ning, Y., Gao, Y., & Gao, W. (2024). Combined role of PEAR1 and GP genes in the mechanism of aspirin resistance and its clinical significance. Molecular & Cellular Biomechanics, 21(4), 1091. https://doi.org/10.62617/mcb1091
Issue
Vol. 21 No. 4 (2024)
Section
Article

Copyright (c) 2024 Yu Ning, Yan Gao, Wei Gao

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright on all articles published in this journal is retained by the author(s), while the author(s) grant the publisher as the original publisher to publish the article.

Articles published in this journal are licensed under a Creative Commons Attribution 4.0 International, which means they can be shared, adapted and distributed provided that the original published version is cited.